MX2015011109A - Composiciones estables de activador de glucoquinasa. - Google Patents
Composiciones estables de activador de glucoquinasa.Info
- Publication number
- MX2015011109A MX2015011109A MX2015011109A MX2015011109A MX2015011109A MX 2015011109 A MX2015011109 A MX 2015011109A MX 2015011109 A MX2015011109 A MX 2015011109A MX 2015011109 A MX2015011109 A MX 2015011109A MX 2015011109 A MX2015011109 A MX 2015011109A
- Authority
- MX
- Mexico
- Prior art keywords
- stable
- glucokinase activator
- activator compositions
- glucokinase
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La invención se relaciona con composiciones farmacéuticas estables que comprenden un activador de glucoquinasa (llamada también glucocinasa (GK)) adecuado para administración oral. La invención también se relaciona con métodos para elaborar y utilizar tales composiciones farmacéuticas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361772022P | 2013-03-04 | 2013-03-04 | |
PCT/US2014/019349 WO2014137797A2 (en) | 2013-03-04 | 2014-02-28 | Stable glucokinase activator compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2015011109A true MX2015011109A (es) | 2015-11-16 |
Family
ID=50424705
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015011109A MX2015011109A (es) | 2013-03-04 | 2014-02-28 | Composiciones estables de activador de glucoquinasa. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20160015638A1 (es) |
EP (1) | EP2964198A2 (es) |
JP (1) | JP6441828B2 (es) |
KR (1) | KR20150123838A (es) |
CN (1) | CN105050585A (es) |
AU (1) | AU2014226290B2 (es) |
CA (1) | CA2903433A1 (es) |
HK (1) | HK1213780A1 (es) |
IL (1) | IL240735A0 (es) |
MX (1) | MX2015011109A (es) |
WO (1) | WO2014137797A2 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2799591C (en) | 2010-05-26 | 2019-06-11 | Transtech Pharma, Inc. | Use of metformin in combination with a glucokinase activator and compositions comprising metformin and a glucokinase activator |
BR112014028622A2 (pt) | 2012-05-17 | 2017-06-27 | Transtech Pharma Llc | composições de ativador de glucoquinase para o tratamento de diabetes |
EP3556354A4 (en) * | 2016-12-15 | 2020-07-01 | Hua Medicine (Shanghai) Ltd. | ORAL PRODUCTION OF A GLUCOKINASE ACTIVATOR AND PRODUCTION METHOD THEREFOR |
MX2020008905A (es) | 2018-06-12 | 2020-12-03 | Vtv Therapeutics Llc | Usos terapeuticos de activadores de glucoquinasa en combinacion con insulina o analogos de insulinas. |
US11857536B2 (en) | 2020-06-04 | 2024-01-02 | Hua Medicine (Shanghai) Ltd. | Glucokinase activator for treating diabetes with renal impairment |
WO2021243645A1 (en) * | 2020-06-04 | 2021-12-09 | Hua Medicine (Shanghai) Ltd. | Glucokinase activator for treating diabetes with renal impairment |
EP4161640A4 (en) * | 2020-06-08 | 2024-01-17 | vTv Therapeutics LLC | SALTS OR COCRYSTALS OF {2-[3-CYCLOHEXYL-3-(TRANS-4-PROPOXY-CYCLOHEXYL)-UREIDO)-THIAZOLE-5-YLSULFANYL}-ACETIC ACID AND USES THEREOF |
AU2021289591A1 (en) * | 2020-06-08 | 2023-01-19 | Vtv Therapeutics Llc | Crystalline forms of {2-[3-cyclohexyl-3-(trans-4-propoxy- cyclohexyl)-ureido]-thiazol-5-ylsulfanyl} -acetic acid and and uses thereof |
KR20240084229A (ko) * | 2022-12-06 | 2024-06-13 | 유노비아 주식회사 | 안정성이 향상된 gpr40 효현제를 유효성분으로 포함하는 약제학적 조성물 |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5552160A (en) * | 1991-01-25 | 1996-09-03 | Nanosystems L.L.C. | Surface modified NSAID nanoparticles |
US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
US6375986B1 (en) * | 2000-09-21 | 2002-04-23 | Elan Pharma International Ltd. | Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate |
US6316029B1 (en) * | 2000-05-18 | 2001-11-13 | Flak Pharma International, Ltd. | Rapidly disintegrating solid oral dosage form |
JP4464129B2 (ja) * | 2001-09-19 | 2010-05-19 | エラン ファーマ インターナショナル,リミティド | ナノ粒子インスリン製剤 |
EP1503737B1 (en) * | 2002-05-06 | 2009-01-07 | Elan Pharma International Limited | Nanoparticulate nystatin formulations |
AU2003241478A1 (en) * | 2002-06-10 | 2003-12-22 | Elan Pharma International, Ltd. | Nanoparticulate sterol formulations and sterol combinations |
JP4533134B2 (ja) * | 2002-06-10 | 2010-09-01 | エラン ファーマ インターナショナル,リミティド | ナノ粒子ポリコサノール製剤および新規なポリコサノールの組合せ |
CN102516240A (zh) | 2004-01-06 | 2012-06-27 | 诺和诺德公司 | 杂芳基脲及其作为葡糖激酶活化剂的用途 |
EP2623095A1 (en) * | 2004-11-16 | 2013-08-07 | Elan Pharma International Limited | Injectable nanoparticulate olanzapine formulations |
UA89513C2 (uk) * | 2004-12-03 | 2010-02-10 | Элан Фарма Интернешнл Лтд. | Стабільна композиція з наночастинок ралоксифену гідрохлориду |
WO2006066063A1 (en) * | 2004-12-15 | 2006-06-22 | Elan Pharma International Ltd. | Nanoparticulate tacrolimus formulations |
US20060159767A1 (en) * | 2004-12-22 | 2006-07-20 | Elan Pharma International Limited | Nanoparticulate bicalutamide formulations |
MX2007008212A (es) * | 2005-01-06 | 2007-08-16 | Elan Pharma Int Ltd | Formulaciones de candesartan en nanoparticulas. |
BRPI0608173A2 (pt) * | 2005-02-24 | 2010-11-09 | Elan Pharma Int Ltd | composição, uso da mesma, e, método de produzir uma composição de docetaxel nanoparticulada ou análogo do mesmo |
KR20070121759A (ko) * | 2005-03-17 | 2007-12-27 | 엘란 파마 인터내셔널 리미티드 | 나노입자형 비스포스포네이트 조성물 |
AU2006227623B2 (en) * | 2005-03-17 | 2011-10-20 | Elan Pharma International Limited | Injectable compositions of nanoparticulate immunosuppressive compounds |
WO2006110809A2 (en) * | 2005-04-12 | 2006-10-19 | Elan Pharma International, Limited | Nanoparticulate lipase inhibitor formulations |
WO2007086914A2 (en) * | 2005-05-10 | 2007-08-02 | Elan Pharma International, Limited | Nanoparticulate clopidogrel formulations |
US20100028439A1 (en) * | 2005-05-23 | 2010-02-04 | Elan Pharma International Limited | Nanoparticulate stabilized anti-hypertensive compositions |
US20060292214A1 (en) * | 2005-06-03 | 2006-12-28 | Elan Pharma International Limited | Nanoparticulate acetaminophen formulations |
JP2008542397A (ja) * | 2005-06-03 | 2008-11-27 | エラン ファーマ インターナショナル リミテッド | ナノ粒子メシル酸イマチニブ製剤 |
US20070059371A1 (en) * | 2005-06-09 | 2007-03-15 | Elan Pharma International, Limited | Nanoparticulate ebastine formulations |
CA2614412A1 (en) * | 2005-07-07 | 2007-01-18 | Elan Pharma International, Limited | Nanoparticulate clarithromycin formulations |
US8367112B2 (en) * | 2006-02-28 | 2013-02-05 | Alkermes Pharma Ireland Limited | Nanoparticulate carverdilol formulations |
KR20090015994A (ko) * | 2006-05-30 | 2009-02-12 | 엘란 파마 인터내셔널 리미티드 | 나노입자형 포사코나졸 제제 |
EP2101735A2 (en) * | 2006-11-28 | 2009-09-23 | Marinus Pharmaceuticals, Inc. | Nanoparticulate formulations and methods for the making and use thereof |
EP2091947A2 (en) * | 2006-12-20 | 2009-08-26 | Takeda San Diego, Inc. | Glucokinase activators |
US20090028680A1 (en) * | 2007-07-27 | 2009-01-29 | Kling Troy L | Intermediate apparatus for towing utility vehicles |
PE20141375A1 (es) * | 2008-05-16 | 2014-10-23 | Takeda San Diego Inc | Activadores de glucoquinasa |
JP2010049784A (ja) * | 2008-07-23 | 2010-03-04 | Hitachi High-Technologies Corp | 複合磁気ヘッドの書込/読出幅測定方法および測定装置 |
AU2010260226A1 (en) * | 2009-06-18 | 2012-02-02 | Abbvie Inc. | Stable nanoparticulate drug suspension |
AU2010261509A1 (en) * | 2009-06-19 | 2012-02-09 | Nanoform Hungary Ltd. | Nanoparticulate telmisartan compositions and process for the preparation thereof |
CN101829061A (zh) * | 2010-05-14 | 2010-09-15 | 无锡纳生生物科技有限公司 | 一种紫杉醇纳米颗粒组合物及其制备方法 |
CA2799591C (en) * | 2010-05-26 | 2019-06-11 | Transtech Pharma, Inc. | Use of metformin in combination with a glucokinase activator and compositions comprising metformin and a glucokinase activator |
-
2014
- 2014-02-28 AU AU2014226290A patent/AU2014226290B2/en not_active Expired - Fee Related
- 2014-02-28 KR KR1020157025036A patent/KR20150123838A/ko not_active Application Discontinuation
- 2014-02-28 MX MX2015011109A patent/MX2015011109A/es unknown
- 2014-02-28 WO PCT/US2014/019349 patent/WO2014137797A2/en active Application Filing
- 2014-02-28 JP JP2015561468A patent/JP6441828B2/ja not_active Expired - Fee Related
- 2014-02-28 CA CA2903433A patent/CA2903433A1/en not_active Abandoned
- 2014-02-28 EP EP14714823.3A patent/EP2964198A2/en not_active Withdrawn
- 2014-02-28 CN CN201480011647.2A patent/CN105050585A/zh active Pending
-
2015
- 2015-08-20 IL IL240735A patent/IL240735A0/en unknown
- 2015-08-31 US US14/840,682 patent/US20160015638A1/en not_active Abandoned
-
2016
- 2016-02-18 HK HK16101756.4A patent/HK1213780A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
WO2014137797A2 (en) | 2014-09-12 |
JP6441828B2 (ja) | 2018-12-19 |
AU2014226290B2 (en) | 2018-11-15 |
US20160015638A1 (en) | 2016-01-21 |
CN105050585A (zh) | 2015-11-11 |
WO2014137797A3 (en) | 2014-10-30 |
AU2014226290A1 (en) | 2015-10-08 |
CA2903433A1 (en) | 2014-09-12 |
EP2964198A2 (en) | 2016-01-13 |
JP2016513625A (ja) | 2016-05-16 |
KR20150123838A (ko) | 2015-11-04 |
HK1213780A1 (zh) | 2016-07-15 |
IL240735A0 (en) | 2015-10-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2015011109A (es) | Composiciones estables de activador de glucoquinasa. | |
AU2018256640A1 (en) | Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives | |
MX2021000550A (es) | Forma de dosis orales de liberacion sostenida de tofacitinib. | |
MX2020005181A (es) | Derivados de aminopiridina como inhibidores de cinasas de la familia de tyro3, axl y mer (tam). | |
MX2021001231A (es) | Compuestos heterociclicos y sus usos. | |
UA116467C2 (uk) | Модулятори p2x7 | |
MX2020001756A (es) | Compuestos deuterados del inhibidor vmat y el uso de dichos compuestos. | |
MX2012007806A (es) | Composiciones farmaceuticas para administracion oral de peptidos de insulina. | |
MX2016001049A (es) | Uso de flecainida como agente anti-conexina y metodo para potenciar los efectos de un farmaco psicotropico. | |
MD20170048A2 (ro) | Formulare pe bază de acetat de abirateronă şi procedee de utilizare a acesteia | |
TN2015000411A1 (en) | Ceftolozane antibiotic compositions | |
UA116889C2 (uk) | Фармацевтична композиція, що містить суміш ізоформ apg101 (cd95-fc) | |
NZ710291A (en) | 2-substituted-6-biarylmethylamino-9-cyclopentyl-9h-purine derivatives, use thereof as medicaments, and pharmaceutical compositions | |
PH12016501686A1 (en) | Pharmaceutical compositions of sitagliptin | |
IN2013MU03641A (es) | ||
MX2015012416A (es) | Compuestos heterociclicos y sus usos. | |
MX2016006087A (es) | Formulaciones de desintegracion rapida y metodos de uso. | |
MX2016002931A (es) | Moduladores del receptor x hepatico (lxr). | |
MX2016002930A (es) | Moduladores del receptor x hepatico (lxr). | |
MX2016005545A (es) | Analogo de la relaxina humana, composicion farmaceutica del mismo y aplicacion farmaceutica del mismo. | |
MX2015016603A (es) | Composiciones de corticosteroides. | |
MX2021003908A (es) | Polipeptidos de accion prolongada y metodos para su produccion y administracion. | |
IN2013CH05770A (es) | ||
IN2013MU03656A (es) | ||
IN2013MU02279A (es) |